CellSource Co

CellSource Co EBITDA per Share

The EBITDA per Share of CellSource Co (4880.T) as of Oct 27, 2026 is 8.41 JPY. In the previous year, EBITDA per Share was 9.36 JPY — a change of -10.18% (lower).

EBITDA per Share

8.41JPY

YoY

-10.18%

Last updated:

EBITDA per Share of CellSource Co is 2025 8.41 JPY. EBITDA per Share of CellSource Co was 2024 9.36 JPY. It decreases by -10.18% lower compared to the previous year.

The CellSource Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
14.97 JPY
Jan 1, 2019
19.31 JPY
Jan 1, 2020
22.10 JPY
Jan 1, 2021
52.32 JPY
Jan 1, 2022
82.45 JPY
Jan 1, 2023
66.39 JPY
Jan 1, 2024
9.36 JPY
Jan 1, 2025
8.41 JPY
The CellSource Co EBITDA per Share history
YEAREBITDA per ShareYoY
8.41JPY-10.18%
9.36JPY-85.89%
66.39JPY-19.48%
82.45JPY+57.57%
52.32JPY+136.78%
22.10JPY+14.44%
19.31JPY+28.97%
14.97JPY+86.97%
8.01JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

EBITDA per Share of CellSource Co is 8.41 JPY in 2025.

EBITDA per Share of CellSource Co changed from 9.36 JPY to 8.41 JPY, representing a -10.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share CellSource Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CellSource Co

All Key Metrics — CellSource Co